The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Alumis Inc. Common Stock 022307102   15,404,782 1,959,896 SH   SOLE   1,959,896 0 0
Arcellx, Inc. Common Stock 03940C100   179,963,055 2,346,630 SH   SOLE   2,346,630 0 0
ARS Pharmaceuticals, Inc. Common Stock 82835W108   42,336,127 4,012,903 SH   SOLE   4,012,903 0 0
CRISPR Therapeutics AG Common Shares H17182108   41,286,711 1,048,951 SH   SOLE   1,048,951 0 0
Design Therapeutics, Inc. Common Stock 25056L103   40,268,357 6,526,476 SH   SOLE   6,526,476 0 0
enGene Holdings Inc. Common Shares 29286M105   4,972,537 747,750 SH   SOLE   747,750 0 0
KALA Bio, Inc. Common Stock 483119202   4,156,644 598,940 SH   SOLE   598,940 0 0
Mineralys Therapeutics Inc. Common Stock 603170101   24,827,079 2,016,822 SH   SOLE   2,016,822 0 0
Nkarta, Inc. Common Stock 65487U108   8,299,999 3,333,333 SH   SOLE   3,333,333 0 0
Oruka Therapeutics, Inc Common Stock 687604108   8,344,099 430,330 SH   SOLE   430,330 0 0
Zenas BioPharma, Inc Common Stock 98937L105   40,225,504 4,911,539 SH   SOLE   4,911,539 0 0